Table 1 Baseline demographic and clinical characteristics and laboratory results according to the presence of myocarditis
From: Bilirubin levels as an independent predictor of myocarditis in patients with COVID-19
Variables | Troponin positive (n = 95) | Troponin negative (n = 95) | p value |
|---|---|---|---|
Age, years | 64.3 ± 9.8 | 62.3 ± 9.3 | 0.158 |
Gender, male, n (%) | 70 (73.7) | 66 (69.5) | 0.52 |
Smoking habits, n (%) | 22 (23.2) | 20 (21.1) | 0.727 |
Hypertension, n (%) | 35 (36.8) | 31 (32.6) | 0.542 |
Hyperlipidemia, n (%) | 23 (24.2) | 21 (22.1) | 0.731 |
Diabetes mellitus, n (%) | 16 (16.8) | 14 (14.7) | 0.691 |
Hemoglobin, g/dL | 13.5 ± 1.4 | 13.8 ± 1.1 | 0.122 |
White blood cell count, × 109/L | 5.9 ± 2.1 | 5.6 ± 2.1 | 0.157 |
Platelet count, × 109/L | 213 (158–235) | 219 (184–262) | 0.081 |
Glucose, mg/dL | 103 (91–123) | 100 (95–115) | 0.465 |
Creatinine, mg/dL | 0.82 ± 0.21 | 0.81 ± 0.18 | 0.804 |
Aspartate aminotransferase, U/L | 30 (21–36) | 29 (23–36) | 0.824 |
Alanine aminotransferase, U/L | 22 (17–29) | 25 (17–41) | 0.318 |
D-dimer, µg/L | 727 (572–995) | 591 (440–790) | 0.001 |
C-reactive protein, mg/L | 30.0 (10–48) | 10.3 (5.8–15.9) | < 0.001 |
CK-MB*, U/L | 19.2 (13.7–27.4) | 17.7 (14.1–20.2) | 0.077 |
Total bilirubin, µmol/L | 9.5 (8.2–12.1) | 7.0 (5.3–8.0) | < 0.001 |
Previous medications | |||
RAASB†, n (%) | 22 (23.2) | 24 (25.3) | 0.735 |
Calcium channel blockers, n (%) | 14 (14.7) | 11 (11.6) | 0.52 |
Beta-blockers, n (%) | 6 (6.3) | 7 (7.4) | 0.774 |
Statin, n (%) | 10 (10.5) | 14 (14.7) | 0.382 |
Antiaggregant, n (%) | 9 (9.5) | 11 (11.6) | 0.636 |
Treatment regimen | |||
Antiviral, n (%) | 86 (90.5) | 83 (87.4) | 0.488 |
Antibiotic, n (%) | 67 (70.5) | 65 (68.4) | 0.753 |
Hydroxychloroquine, n (%) | 25 (26.3) | 22 (23.2) | 0.614 |
LMWH‡, n (%) | 89 (93.7) | 87 (91.6) | 0.579 |
Corticosteroid, n (%) | 48 (50.5) | 44 (46.3) | 0.561 |